Literature DB >> 26662104

Anticancer effects of tributyltin chloride and triphenyltin chloride in human breast cancer cell lines MCF-7 and MDA-MB-231.

Luba Hunakova1, D Macejova2, L Toporova2, J Brtko2.   

Abstract

Triorganotin compounds induce hormonal alterations, i.e., endocrine-disrupting effects in mammals, including humans. Tributyltin chloride (TBT-Cl) and triphenyltin chloride (TPT-Cl) are known to function as nuclear retinoid X receptor (RXR) agonists. Their cytotoxic effects in ER(+) luminal human breast cancer cell line MCF-7 and ER(-) basal-like human breast cancer cell line MDA-MB-231 were examined. We observed significantly higher toxicity of TBT-Cl in comparison with TPT-Cl in both cell lines. Comparable apoptosis-inducing concentrations were 200 and 800 nM, respectively, as shown by PARP cleavage and FDA staining. Both compounds activated executive caspases in the concentration-dependent manner in MDA-MB-231 cells, but the onset of TPT-Cl-induced caspase-3/7 activation was delayed in comparison with TBT-Cl. Both compounds slowed down the migration of these highly invasive cells, which was accompanied by RARbeta upregulation. Other RAR and RXR expressions were differentially modulated by studied organotins in both cell lines.

Entities:  

Keywords:  All-trans retinoic acid receptor; Cytotoxicity; Human breast carcinoma cells; Migration; Retinoid X receptor; Triorgatonins

Mesh:

Substances:

Year:  2015        PMID: 26662104     DOI: 10.1007/s13277-015-4524-6

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  32 in total

1.  Comparative analysis of apoptosis in HL60 detected by annexin-V and fluorescein-diacetate.

Authors:  D Bartkowiak; S Högner; H Baust; W Nothdurft; E M Röttinger
Journal:  Cytometry       Date:  1999-11-01

Review 2.  Organometallic compounds in oncology: implications of novel organotins as antitumor agents.

Authors:  Angela Alama; Bruno Tasso; Federica Novelli; Fabio Sparatore
Journal:  Drug Discov Today       Date:  2009-02-11       Impact factor: 7.851

3.  Organotin compounds, including butyltins and octyltins, in house dust from Albany, New York, USA.

Authors:  Kurunthachalam Kannan; Shin Takahashi; Naohiro Fujiwara; Hazuki Mizukawa; Shinsuke Tanabe
Journal:  Arch Environ Contam Toxicol       Date:  2010-04-09       Impact factor: 2.804

Review 4.  Role of retinoids, rexinoids and thyroid hormone in the expression of cytochrome p450 enzymes.

Authors:  Julius Brtko; Zdenek Dvorak
Journal:  Curr Drug Metab       Date:  2011-02       Impact factor: 3.731

5.  In vitro approaches to evaluate toxicity induced by organotin compounds tributyltin (TBT), dibutyltin (DBT), and monobutyltin (MBT) in neuroblastoma cells.

Authors:  Martiña Ferreira; Lucía Blanco; Alejandro Garrido; Juan M Vieites; Ana G Cabado
Journal:  J Agric Food Chem       Date:  2013-04-18       Impact factor: 5.279

6.  Effects of low dose treatment of tributyltin on the regulation of estrogen receptor functions in MCF-7 cells.

Authors:  Shruti Sharan; Kumar Nikhil; Partha Roy
Journal:  Toxicol Appl Pharmacol       Date:  2013-03-21       Impact factor: 4.219

7.  Metabolism of tributyltin and triphenyltin by rat, hamster and human hepatic microsomes.

Authors:  Shuji Ohhira; Masatomo Watanabe; Hisao Matsui
Journal:  Arch Toxicol       Date:  2002-12-17       Impact factor: 5.153

Review 8.  Renaissance of the biologically active vitamin A derivatives: established and novel directed therapies for cancer and chemoprevention.

Authors:  J Brtko; J Thalhamer
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

9.  Caspase-10 is the key initiator caspase involved in tributyltin-mediated apoptosis in human immune cells.

Authors:  Harald F Krug
Journal:  J Toxicol       Date:  2012-01-12

10.  Retinoic acid reduces migration of human breast cancer cells: role of retinoic acid receptor beta.

Authors:  Marina Ines Flamini; Gisel Valeria Gauna; Mayra Lis Sottile; Beatriz Silvina Nadin; Angel Matias Sanchez; Laura Maria Vargas-Roig
Journal:  J Cell Mol Med       Date:  2014-04-10       Impact factor: 5.310

View more
  6 in total

1.  Anticancer efficacies of arsenic disulfide through apoptosis induction, cell cycle arrest, and pro-survival signal inhibition in human breast cancer cells.

Authors:  Yuxue Zhao; Bo Yuan; Kenji Onda; Kentaro Sugiyama; Sachiko Tanaka; Norio Takagi; Toshihiko Hirano
Journal:  Am J Cancer Res       Date:  2018-03-01       Impact factor: 6.166

2.  Genotoxic Effects of Tributyltin and Triphenyltin Isothiocyanates, Cognate RXR Ligands: Comparison in Human Breast Carcinoma MCF 7 and MDA-MB-231 Cells.

Authors:  Luba Hunakova; Eva Horvathova; Karolina Majerova; Pavel Bobal; Jan Otevrel; Julius Brtko
Journal:  Int J Mol Sci       Date:  2019-03-09       Impact factor: 5.923

3.  Effect of IDH3a on glucose uptake in lung adenocarcinoma: A pilot study based on [18 F]FDG.

Authors:  Bulin Du; Tong Sun; Xuena Li; Yao Diao; Yaming Li
Journal:  Cancer Med       Date:  2019-07-29       Impact factor: 4.452

4.  The Effect of Aflatoxin B1 on Tumor-Related Genes and Phenotypic Characters of MCF7 and MCF10A Cells.

Authors:  Mowaffaq Adam Ahmed Adam; Laina Zarisa Muhd Kamal; Mahibub Kanakal; Dinesh Babu; Saad Sabbar Dahham; Yasser Tabana; Bronwyn Lok; Brittany M Bermoy; Muhammad Amir Yunus; Leslie Thian Lung Than; Khaled Barakat; Doblin Sandai
Journal:  Int J Mol Sci       Date:  2022-10-06       Impact factor: 6.208

5.  Triorganotin Derivatives Induce Cell Death Effects on L1210 Leukemia Cells at Submicromolar Concentrations Independently of P-glycoprotein Expression.

Authors:  Viera Bohacova; Mario Seres; Lucia Pavlikova; Szilvia Kontar; Martin Cagala; Pavel Bobal; Jan Otevrel; Julius Brtko; Zdena Sulova; Albert Breier
Journal:  Molecules       Date:  2018-05-01       Impact factor: 4.411

6.  Tributyltin chloride (TBT) induces RXRA down-regulation and lipid accumulation in human liver cells.

Authors:  Fabio Stossi; Radhika D Dandekar; Hannah Johnson; Philip Lavere; Charles E Foulds; Maureen G Mancini; Michael A Mancini
Journal:  PLoS One       Date:  2019-11-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.